Search

The invasive stages of parasites of the protozoan phylum Apicomplexa have the capacity to traverse host tissues and invade host cells using a unique type of locomotion called gliding motility. Gliding motility is powered by a sub-membranous actin-myosin motor, and the force generated by the motor is transduced to the parasite surface by transmembrane proteins of the apicomplexan-specific thrombospondin-related anonymous protein (TRAP) family. These proteins possess short cytoplasmic tails that interact with the actin-myosin motor via the glycolytic enzyme aldolase. Gliding motility of the Plasmodium sporozoite, the stage of the malaria parasite that is transmitted by the mosquito to the mammalian host, depends on the TRAP protein. We describe a second protein, herein termed TREP, which also plays a role in the gliding motility of the Plasmodium sporozoite. TREP is a transmembrane protein that possesses a short cytoplasmic tail typical of members of the TRAP family of proteins, as well as a large extracellular region that contains a single thrombospondin type 1 repeat domain. TREP transcripts are expressed predominantly in oocyst stage sporozoites. Plasmodium berghei sporozoites harbouring a disrupted TREP gene have a highly diminished capacity to invade mosquito salivary glands and display a severe defect in gliding motility. We conclude that the gliding motility of the Plasmodium sporozoite in the mosquito depends on at least two proteins, TRAP and TREP.

A resurgence in infant and adult pertussis cases has been observed in many countries around 25 years after the introduction of generalised vaccination. An antigenic differences between circulating isolates and vaccinal strains, due to changes in vaccine procedures, could be due to this resurgence. In this study, we analysed the genome and antigenic expression of vaccinal strains of the Aventis Pasteur whole-cell pertussis vaccine from multiple lots stored since 1984. Despite lyophilisation having been performed on these strains for over 30 years, their genome remain conserved, and they still express the major toxins and adhesins. A study in mice confirmed that vaccine lots were highly immunogenic. In conclusion, there is no evidence to suggest that many years of production have resulted in alteration in the French vaccinal strains which quality has remained consistent since its introduction, this can explain its continued efficacy, effectiveness and the lack of epidemics in France.

When pertussis toxin S1 subunit and pertactin structural genes in Bordetella pertussis clinical isolates from France and Germany were sequenced, 3 previously described S1 subunit types (S1 A, B and E), and 4 pertactin types (PRN A, B, C, A*) were found. PRN A*, present in the WHO reference strain 18323, was not described previously. In a respiratory mouse model, a tricomponent acellular pertussis vaccine (Infanrix) was highly effective in promoting lung clearance of all isolates expressing different S1 subunit and pertactin suggesting that use of acellular vaccine will not increase the risks of pertussis infection by these B. pertussis variants.